EECP Research in 2024-2026: What the Newest Studies Show
The evidence base for EECP keeps growing. Between 2024 and 2026, researchers published new systematic reviews and randomized trials on Enhanced External Counterpulsation. The short version: the strongest evidence remains in refractory angina, and newer studies continue to examine heart failure, exercise capacity and quality of life. Here is what the newest research actually shows.
Key Points
- A 2026 systematic review and meta-analysis found EECP improved angina class, reduced nitroglycerin use, and improved functional capacity and quality of life versus standard medical therapy
- A 2025 randomized trial in ischemic heart failure reported greater exercise tolerance and improved left ventricular function versus sham treatment
- EECP devices are FDA-cleared, not FDA-approved, for specific cardiovascular indications
- A standard course is typically 35 one-hour sessions over about seven weeks
- EECP does not replace medical care; an evaluation with a qualified professional comes first
- A 2026 cardiac-rehabilitation cohort study associated EECP with fewer major adverse cardiovascular events
What Is the Newest Evidence on EECP?
The most recent summary-level evidence is a 2026 systematic review and meta-analysis of EECP versus standard medical therapy for chronic refractory angina. Across the trials included, EECP was associated with improvements in angina class, reduced use of sublingual nitroglycerin, and better functional capacity and quality of life.
A 2025 randomized, placebo-controlled trial in people with ischemic heart failure compared long-term EECP with sham counterpulsation and reported greater gains in exercise tolerance, improved left ventricular systolic function and reduced myocardial stress in the EECP group.
Keep the word 'may' in mind. Studies vary in size and design, and EECP is not appropriate for everyone. These results describe groups in trials, not guarantees for any individual.
Additional 2025 and 2026 studies keep extending the picture. A 2026 analysis of patients in cardiac rehabilitation after acute coronary syndrome associated EECP with a lower rate of major adverse cardiovascular events, driven mainly by less recurrent angina and fewer repeat revascularizations. In chronic heart failure, a 2025 study combining cardiac rehabilitation with EECP reported improved heart rate variability and autonomic function, and a 2025 trial in heart failure with reduced ejection fraction reported improved cardiac function, symptoms and quality of life.
What Is EECP Cleared For?
EECP devices are cleared by the FDA through the 510(k) pathway for specific cardiovascular uses, including the treatment of stable and unstable angina, acute myocardial infarction, cardiogenic shock and congestive heart failure. 'Cleared' is not the same as 'approved': clearance reflects that a device is substantially equivalent to a legally marketed device for its intended use.
Medicare covers EECP for severe, refractory angina under National Coverage Determination 20.20, typically for patients with class III or IV angina who have not responded to maximal medical therapy and are not candidates for revascularization.
What Does a Standard EECP Course Look Like?
The standard course is 35 one-hour sessions, typically one per day, five days per week, over about seven weeks. Each session involves lying comfortably while cuffs around the calves, thighs and hips inflate and deflate in rhythm with your heartbeat.
Some patients discuss repeat courses with their care team if they responded well initially. Whether EECP is right for you depends on your health history, which is why an evaluation is the correct first step.
What Does This Mean for Someone in Utah?
EECP availability is extremely limited in Utah, and the therapy is not offered at most clinics. Thrive EECP in Draper provides EECP and serves patients from across the South Salt Lake Valley and northern Utah County communities, many of whom travel specifically for this treatment.
If you are curious whether EECP might be relevant for your situation, the next step is a conversation, not a commitment. Request a free consultation or call 385-330-0358 to talk with the team at Thrive EECP, 1111 East Draper Parkway, Draper, Utah.
Sources & References
Independent, authoritative sources used in this article, linked so you can verify the details yourself. Information here is educational and not a substitute for medical advice.
- EECP vs. standard medical therapy for chronic refractory angina: systematic review and meta-analysis (Biomedicines, 2026)
- Long-term EECP in ischemic heart failure: randomized, placebo-controlled trial (Journal of Cardiovascular Development and Disease, 2025)
- Enhanced External Counterpulsation outcomes study, standard 35-hour protocol (PubMed, 2024)
- CMS National Coverage Determination 20.20: External Counterpulsation for Severe Angina
- Cigna medical coverage policy: external counterpulsation (FDA 510(k) status and guideline context)
- Cardiac rehabilitation based on EECP in patients with acute coronary syndrome (PubMed, 2026)
- Cardiac rehabilitation combined with EECP and heart rate variability in chronic heart failure (PubMed, 2025)
- EECP effects on cardiac function, symptoms and quality of life in heart failure with reduced ejection fraction (ScienceDirect, 2025)
Want to Explore This Further?
This article is part of the Thrive EECP Health Library in Draper, Utah. If the topic above sounds relevant to you, the next step is a free, no-pressure conversation about your goals.
About the Author
This article was authored and curated by Phil Kim for the Thrive EECP Health Library, with content guidance from the Thrive team. It is educational information, not medical advice, and does not create a patient relationship. Always consult a qualified healthcare professional about your health.
